Several members of the Arenaviridae family cause hemorrhagic fever disease in humans and pose serious public health problems in their geographic regions of endemicity as well as a credible biodefense threat. To date, there have been no FDA-approved arenavirus vaccines, and current antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effective. Arenaviruses are enveloped viruses with a bisegmented negative-stranded RNA genome. Each genome segment uses an ambisense coding strategy to direct the synthesis of two viral polypeptides in opposite orientations, separated by a noncoding intergenic region. Here we have used minigenome-based approaches to evaluate expression levels of reporter genes from the nucleoprotein (NP) and glycoprotein precursor (GPC) loci within the S segment of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). We found that reporter genes are expressed to higher levels from the NP than from the GPC locus. Differences in reporter gene expression levels from the NP and GPC loci were confirmed with recombinant trisegmented LCM viruses. We then used reverse genetics to rescue a recombinant LCMV ( A renaviruses are enveloped viruses with a bisegmented negative-strand (NS) RNA genome that cause chronic infections of rodents across the world (1). Zoonotic transmission through either direct contact with contaminated material or inhalation of aerosolized particles can result in severe infection in humans (1). Several arenaviruses, mainly, Lassa virus (LASV), the agent responsible for Lassa fever (LF) in western Africa, and Junín virus (JUNV), the causative agent of Argentine hemorrhagic fever (AHF) in the Argentinean Pampas, cause severe HF diseases in humans that are associated with high morbidity and significant mortality, posing important health problems in their regions of endemicity (1-3). Importantly, increased travel has resulted in the importation of LF into nonendemic metropolitan regions around the globe, including the United States (4, 5), Europe (6), and Japan (7). Moreover, similarly to the situation recently illustrated with the 2014 Ebola virus outbreak in western Africa (8, 9), evidence indicates that regions of LASV endemicity are expanding. In addition, the recent identification of two novel HF-causing arenaviruses, Chapare virus in Bolivia (10) and Lujo virus in South Africa (11), has further reinforced concerns about the emergence of novel HF-causing arenaviruses. Additionally, evidence indicates that the lymphocytic choriomeningitis virus (LCMV) prototypic arenavirus, distributed worldwide, is a neglected human pathogen of clinical significance (12-15). Besides their impact in human public health, arenaviruses pose also a credible biodefense threat, and six of them, including LCMV, LASV, and JUNV, are classified as NIAID category A agents (2, 16). Threats posed by humanpathogenic arenaviruses are further aggravated by the lack of FDA-approved vaccines (1) and by current antiarenaviral therapy 
A renaviruses are enveloped viruses with a bisegmented negative-strand (NS) RNA genome that cause chronic infections of rodents across the world (1) . Zoonotic transmission through either direct contact with contaminated material or inhalation of aerosolized particles can result in severe infection in humans (1) . Several arenaviruses, mainly, Lassa virus (LASV), the agent responsible for Lassa fever (LF) in western Africa, and Junín virus (JUNV), the causative agent of Argentine hemorrhagic fever (AHF) in the Argentinean Pampas, cause severe HF diseases in humans that are associated with high morbidity and significant mortality, posing important health problems in their regions of endemicity (1) (2) (3) . Importantly, increased travel has resulted in the importation of LF into nonendemic metropolitan regions around the globe, including the United States (4, 5) , Europe (6) , and Japan (7) . Moreover, similarly to the situation recently illustrated with the 2014 Ebola virus outbreak in western Africa (8, 9) , evidence indicates that regions of LASV endemicity are expanding. In addition, the recent identification of two novel HF-causing arenaviruses, Chapare virus in Bolivia (10) and Lujo virus in South Africa (11) , has further reinforced concerns about the emergence of novel HF-causing arenaviruses. Additionally, evidence indicates that the lymphocytic choriomeningitis virus (LCMV) prototypic arenavirus, distributed worldwide, is a neglected human pathogen of clinical significance (12) (13) (14) (15) . Besides their impact in human public health, arenaviruses pose also a credible biodefense threat, and six of them, including LCMV, LASV, and JUNV, are classified as NIAID category A agents (2, 16) . Threats posed by humanpathogenic arenaviruses are further aggravated by the lack of FDA-approved vaccines (1) and by current antiarenaviral therapy being limited to the off-label use of the nucleoside analog ribavirin, which is only partially effective and associated with side effects (17) (18) (19) (20) (21) . Therefore, there is an unmet need to develop both safe and protective prophylactics (vaccines) to combat pathogenic arenavirus infections in humans.
The live attenuated Candid#1 strain of JUNV has been shown to be an effective vaccine against AHF (22) , but outside Argentina Candid#1 has only investigational new drug (IND) status, and studies addressing long-term immunity and safety have not been conducted (23) . In addition, Candid#1 phenotypic stability has been questioned (24) and two independent studies have linked a single amino acid change in the viral glycoprotein precursor (GPC) to enhanced virulence (25, 26) . Moreover, unpublished studies from S. Paessler and colleagues at University of Texas Medical Branch (UTMB)-Galveston have shown that Candid#1 does not protect against LASV (personal communication). Several vaccine platforms expressing different LASV antigens have shown promising results in animal models (27) (28) (29) (30) . However, epidemiological studies strongly support the argument that development of a live attenuated vaccine would be the most feasible and attractive approach to control LASV, as well as other potentially emerging human-pathogenic arenaviruses, as such vaccines induce robust and long-term cellular and humoral immune protective responses following a single-dose immunization without the use of adjuvants (3, 31, 32) . In this regard, the Mopeia virus (MOPV)/ LASV ML29 reassortant is a LASV live attenuated candidate vaccine that has been shown to provide post-exposure protection and to be safe and immunogenic in guinea pigs and small nonhuman primates (33) (34) (35) . However, the mechanisms of ML29 attenuation remain poorly understood and additional mutations in ML29 or reassortments between ML29 and circulating virulent strains of LASV could result in viruses with enhanced virulence (36) . Here we have explored the distinctive organization of the arenavirus genome as an unique opportunity for the rational design of live attenuated vaccines based on rearrangement of the viral genes to disrupt normal viral gene expression and, therefore, viral fitness. The rationale for this approach is further supported by current efforts aimed at evaluating reorganization of the viral genome as a novel strategy for the generation of live attenuated vaccine candidates for a variety of DNA and RNA viruses (37) (38) (39) (40) (41) (42) (43) (44) (45) .
Each of the two arenavirus genome segments uses an ambisense coding strategy to direct the synthesis of two viral polypeptides in opposite directions that are separated by a noncoding intergenic region (IGR) (1) . The large (L) segment encodes the viral RNA (vRNA)-dependent RNA polymerase (RdRp or L polymerase) and the matrix protein (Z), which plays a major role in viral assembly and budding (46) . The small (S) segment encodes the viral GPC involved in receptor binding and cell entry and the viral nucleoprotein (NP), the most abundant viral product in infected cells and virions and the main component of the viral ribonucleoprotein (vRNP) that, together with L, directs viral genome replication and gene transcription (47) . In addition, arenavirus NP mediates the incorporation of the vRNPs into mature infectious virions by interacting with Z (48, 49) . NP has also been shown to counteract the cellular host type I interferon (IFN-I) and inflammatory responses (50) (51) (52) (53) (54) (55) . Arenavirus gene transcription is mediated by the viral promoters located within the untranslated regions (UTRs) at the 3= termini of the vRNA and complementary (c)RNA species (1, 56) . Thus, NP and L proteins, located at the 3= end of the S and L viral segments, respectively, are translated from mRNAs with antigenomic sense polarity transcribed directly from the vRNAs and are the first arenaviral proteins encoded upon viral infection (1) . On the other hand, GPC and Z proteins located at the 5= end of the S and L vRNA segments, respectively, are translated from mRNA derived from antigenome cRNA species after replication of the vRNAs (1) . Viral cRNAs are also the template for newly synthesized vRNAs (1) . Transcription termination is mediated by the IGR that functions as a bona fide transcription termination signal for the arenavirus polymerase complex (1, 57) . In this report, we have used reverse genetics approaches (58) (59) (60) to generate a recombinant LCMV (rLCMV) where the viral NP and GPC products encoded by the S segment were translocated (rLCMV/TransS). The rescued rLCMV/TransS exhibited reduced growth kinetics in culture cells that correlated with viral attenuation in a mouse model of fatal lymphocytic choriomeningitis (LCM) caused by intracranial (i.c.) inoculation with wild-type LCMV (rLCMV/WT). Notably, rLCMV/TransS was able to confer, upon a single immunization dose in mice, full protection against a lethal challenge with rLCMV/WT. Using our arenavirus recombinant trisegmented (r3) platform (58-61), we found that attenuation of rLCMV/TransS correlated with reduced NP expression levels during viral infection. Our findings demonstrate the potential of arenavirus genome rearrangement for the rational design of live attenuated vaccines to combat diseases caused by human-pathogenic arenaviruses.
MATERIALS AND METHODS
Cells and viruses. A549 human lung adenocarcinoma epithelial (ATCC CCL-185), 293T human embryonic kidney (ATCC CRL-11268), Vero African green monkey kidney epithelial (ATCC CCL-81), and BHK-21 baby hamster kidney (ATCC CCL-10) cells were grown in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Inc.) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml) and maintained in a 5% CO 2 humidified atmosphere at 37°C.
Recombinant wild-type (rLCMV/WT) and translocated S segment (rLCMV/TransS) LCM viruses and trisegmented WT and translocated S segment (r3LCMV/WT and r3LCMV/TransS, respectively) LCM viruses were rescued and propagated in BHK-21 cells, as described previously (58, 59, 61, 62) . All rLCM and r3LCM viruses are based on Armstrong strain ARM53b (58) (59) (60) (61) .
Plasmids. LCMV NP and L pCAGGS mammalian expression plasmids, as well as the L segment vRNA expression plasmid driven by the murine polymerase-I promoter (mpPOL-I L), have been described previously (58) (59) (60) 63) . The mpPOL-I plasmid driving S segment vRNA expression and lacking the viral NP and GPC open reading frames (ORFs) (mpPOL-I S ⌬NPϩBbsI/⌬GPCϩBsmBI) was generated by de novo cDNA synthesis (Biomatik). Viral (NP or GPC) and reporter (green fluorescent protein [GFP] or Gaussia luciferase [Gluc]) ORFs were then amplified by PCR with specific primers containing either BbsI (NP) or BsmBI (GPC) restriction sites and cloned into the NP or GPC locus, respectively. MG assays. Human 293T cells (6.5 ϫ 10 5 cells/well; 12-well format; triplicate) were transiently cotransfected, using Lipofectamine 2000 (LPF 2000) (Invitrogen), with 0.6 g of pCAGGS L, 0.15 g of pCAGGS NP, 0.5 g of the indicated green fluorescent protein (GFP) and Gaussia luciferase (Gluc) dual-reporter minigenome (MG) plasmids driven by a human polymerase-I promoter (hpPOL-I GFP/Gluc or hpPOL-I Gluc/GFP), and 0.1 g of a mammalian expression vector encoding Cypridina noctiluca luciferase (Cluc) under the control of the constitutively active simian virus 40 (SV40) promoter (pSV40-Cluc; New England BioLabs) to normalize transfection efficiencies (58, 63) . Reporter gene expression was determined by fluorescence microscopy (GFP) using a Leica fluorescence microscope and by luminometry (Gluc) using a Lumicount luminometer (Packard) at 24, 48, and 72 h posttransfection (p.t.). Microscope images were pseudocolored using Adobe Photoshop CS4 (v11.0) software. Luciferase gene activities were determined using Biolux Gaussia and Cypridina Luciferase Assay kits (New England BioLabs). Reporter gene activation (Gluc) is indicated as fold induction over 293T cells transfected with a negative pCAGGS empty plasmid control instead of the viral NP. Mean values and standard deviations were calculated and statistical analysis were performed using a two-tailed Student's t test and Microsoft Excel software (58, 63) . At 72 h posttransfection, cells were also subjected to flow cytometry analysis, and percentages of GFP-positive (GFP ϩ ) cells and mean fluorescence intensities (MFI) of the FL1-gated cell population were determined using FlowJo software (Tree Star). Virus rescue. Methods for generating rLCM viruses have been described previously (58) (59) (60) (61) (62) . Briefly, BHK-21 cells (1 ϫ 10 6 cells/well; 6-well format) were transiently cotransfected with 0.8 g of the pCAGGS NP, 1 g of the pCAGGS L, 1.4 g of the mpPOL-I L, and 0.8 g of the mpPOL-I encoding the wild-type (WT) or the translocated (Trans) S segment, using 2.5 g LPF 2000/g transfected DNA. At 72 h p.t., cells were trypsinized and reseeded into 10-cm-diameter dishes for further incubation. Tissue culture supernatants (TCS) were collected after an additional 72 h, virus titers were determined using an immunofocus assay in Vero cells (4 ϫ 10 4 cells/well; 96-well format), and virus antigen was detected at 18 h postinfection (p.i.) using the LCMV NP monoclonal antibody (clone 1.1.3). To rescue r3LCM viruses, BHK-21 cells were transiently cotransfected as described above but with 0.8 g of the two different mpPOL-I S segments (58) (59) (60) . For r3LCM viruses, successful rescue was directly monitored by fluorescence microscopy (GFP).
Virus growth kinetics and immunofluorescence assays. A549, BHK-21, and Vero cells (1.25 ϫ 10 5 cells/well; 24-well format; triplicate) were infected at a multiplicity of infection (MOI) of 0.01. After 90 min of incubation in a 5% CO 2 humidified atmosphere at 37°C, the virus inoculum was removed and cells were maintained in reduced-serum (2% FBS) DMEM. TCS were collected at the indicated times postinfection (p.i.) to measure viral titers (for both rLCMV and r3LCMV), as well as Gaussia luciferase reporter activity (r3LCMV only). Virus titers were determined by fluorescence microscopy (r3LCMV) or by immunofluorescence (rLCMV) using NP monoclonal antibody 1.1.3. Mean values and standard deviations were calculated using Microsoft Excel software (58) (59) (60) . At 96 h postinfection, cells were subjected to flow cytometry analysis, and percentages of GFP ϩ cells and mean fluorescence intensities (MFI) of the FL1-gated cell population were determined using FlowJo software (Tree Star).
Flow cytometry. Flow cytometry analyses were performed at the latest time point of each experiment (72 h for minigenome assays and 96 h for viral infections). Cells were first washed with phosphate-buffered saline (PBS) and then trypsinized and pelleted by low-speed centrifugation. Cells were next fixed with 4% paraformaldehyde diluted in PBS for 20 min at room temperature. Fixation medium was removed after 20 min, and the reaction mixture was washed twice with 5% FBS-PBS prior to analysis. Levels of GFP-positive (GFP ϩ ) cells were determined by gating on the FL1-gated cell population using a C6 4-color cytometer (Accuri). Percentages of GFP ϩ cells and mean fluorescence intensities (MFI) were analyzed using FlowJo software (Tree Star).
Persistent infections. A549, BHK-21, and Vero cells were infected (MOI of 0.1) and were subjected 48 h later to the first passage (P1) (1:10 dilution). When cells reached 100% confluence, they were seeded (P2) onto coverslips placed on M24 wells (7 ϫ 10 4 cells/M24 well) and 36 h later were fixed with 4% paraformaldehyde and examined for expression of virus NP antigen by immunofluorescence using a rat monoclonal antibody (VL4) to NP directly conjugated to Alexa Fluor 488. Nuclei were visualized by DAPI (4=,6-diamidino-2-phenylindole) staining.
Reverse transcription-PCR (RT-PCR).
BHK-21 cells (1 ϫ 10 6 cells/ well; 6-well format) were infected with the rLCM viruses at an MOI of 0.01. At 72 h p.i., total RNA was extracted using TRIzol following manufacturer recommendations (Invitrogen) and reverse transcribed to cDNA using random hexamer DNA primers. Primers specific to the 3= and 5= UTR of the LCMV S segment were combined with reverse 3= primers for the viral NP (NP3=) and GPC (GPC3=). Amplified gene products were analyzed on a 1% DNA agarose gel and confirmed by sequencing. Primer sequences are available upon request.
Mouse experiments. All animal experiments were done under a protocol approved by The Scripps Research Institute IACUC. To evaluate virulence in vivo, 6-week-old immunocompetent C57BL/6J (B6) male mice (n ϭ 8) were inoculated intracranially (i.c.) with 10 3 PFU of the rLCMV/WT or rLCMV/TransS, or with the virus diluent PBS, and were monitored daily for 12 days for development of clinical symptoms (morbidity) and survival (mortality). To evaluate the protection efficacy of rLCMV/TransS, 6-week-old immunocompetent B6 male mice (n ϭ 8) were first mock immunized with PBS or immunized with rLCMV/TransS or with rLCMV/WT intraperitoneally (i.p.) with 10 5 PFU. At 4 weeks p.i., mice were lethally challenged with rLCMV/WT (i.c., 10 3 PFU) and monitored for development of clinical symptoms and survival for 12 days (59, 63) .
RESULTS

Effect of locus position within the LCMV S segment on levels of viral protein expression.
To evaluate how the locus location of viral ORFs within the viral S segment (Fig. 1A ) affected protein expression, we generated two minigenome (MG) reporter plasmids (Fig. 1B) . In one, the NP and GPC ORFs were replaced by GFP and Gaussia luciferase (Gluc) reporters, respectively (GFP/ Gluc). In the other, NP and GPC ORFs were replaced by Gluc and GFP, respectively (Gluc/GFP). We used these MG reporter plasmids to evaluate reporter gene expression levels from the NP and GPC loci using our MG assay (58, 59) . We observed higher levels of GFP expression from the NP (GFP/Gluc) than from the GPC (Gluc/GFP) loci at all times posttransfection examined (Fig. 1C) . Flow cytometry analysis indicated that cell transfected with the GFP/Gluc MG displayed an ϳ2-fold increase (24.3 ϫ 10 4 versus 13.1 ϫ 10 4 ) in mean fluorescence intensity (MFI) compared to cells transfected with the Gluc/GFP MG (Fig. 1D) . Similar results were obtained with Gluc expression levels (Fig. 1E) , as quantification of Gluc expression indicated a 2-to-3-fold increase in Gluc activity when the reporter gene was expressed from the NP locus compared to the GPC locus (Gluc/GFP versus GFP/Gluc).
To confirm this differential gene expression, we used reverse genetic approaches (58) (59) (60) to rescue recombinant trisegmented (r3) LCM viruses where GFP had replaced the viral NP and Gluc the viral GPC (r3LCMV/WT GFP/Gluc; Fig. 2A, left) or a r3LCMV where the Gluc and GFP substitutes replaced the viral NP and GPC, respectively (r3LCMV/WT Gluc/GFP; Fig. 2A,  right) . Using these r3LCMV, we evaluated expression of GFP ( (Fig. 2C ) in BHK-21 cells at different times postinfection (MOI of 0.01). Consistent with the results from MG-based assays, GFP and Gluc expression levels were significantly higher when placed into the NP locus. These results were further corroborated by flow cytometry analysis, as an increase in GFP intensity was observed in r3LCMV/WT GFP/Gluc-infected cells compared to r3LCMV/WT Gluc/GFP cells (Fig. 2B) , although the percentages of infected cells were similar in the two cases. Importantly, differences in reporter gene expression were not due to differences between the two r3LCM viruses in viral growth kinetics (Fig. 2D) .
2B) and Gluc
Rearrangement of the LCMV genome by translocation of the S segment ORFs. On the basis of our results obtained using MG (Fig. 1)-and r3LCMV (Fig. 2) -based approaches, we reasoned that a rLCMV in which the viral NP and GPC ORFs were swapped (rLCMV/TransS) would exhibit decreased viral fitness compared to rLCMV/WT. We successfully rescued rLCMV/TransS (Fig. 3A) and confirmed its genetic identity by RT-PCR using RNA isolated from infected BHK-21 cells (Fig. 3B) . Sequencing results (data not shown) unequivocally confirmed the identity of the rLCMV/ TransS. We next evaluated the growth kinetics of rLCMV/TransS in A549 (Fig. 4A) , BHK-21 (Fig. 4B) , and Vero (Fig. 4C) cells. In all cell types, NP and GPC expression (left panels) and viral replication (right panels) of rLCMV/TransS were affected at all times postinfection examined compared to the rLCMV/WT results.
Safety and protective efficacy of rLCMV/TransS. We next examined whether the decreased fitness of rLCMV/TransS observed in cultured cells correlated with in vivo attenuation, which would support the potential implementation of arenavirus genome rear- rangement for the development of live attenuated vaccine candidates. For this, we used the well-established mouse model of fatal LCM following intracranial inoculation with LCMV (59). We infected 6-week-old male B6 mice i.c. with 10 3 PFU of rLCMV/WT or rLCMV/TransS or inoculated them with PBS as a control (Table 1). As predicted, all mice infected with rLCMV/WT developed clinical symptoms of LCM disease by 6 days p.i., and all of those mice died within 8 days after inoculation. In contrast, all mice infected with rLCMV/TransS remained free of clinical symptoms throughout the duration of the experiment (12 days) and survived, similarly to the PBS control group. We then assessed the protective capability of rLCMV/TransS against a lethal challenge (i.c. 10 3 PFU) with rLCMV/WT in a standard protocol of LCMV immunization (10 5 PFU, i.p. route) ( Table 2) . As expected, PBSinoculated mice succumbed to rLCMV/WT lethal challenge within 8 days postinfection, while a single administration of rLCMV/TransS was capable of inducing protective immunity to the subsequent rLCMV/WT lethal challenge, and all mice remained free of clinical symptoms throughout the duration of the experiment (12 days). These results demonstrated the feasibility of using rLCMV/TransS as a live attenuated vaccine candidate against LCMV.
Generation of r3LCMV/TransS as vaccine vectors. To further validate the attenuation of LCMV by reorganization of the viral S segment and to demonstrate the potential use of r3LCM viruses containing a TransS segment for the development of vaccine vectors, we generated r3LCMV/TransS (Fig. 5A, right) . Growth kinetics in A549 (Fig. 5B), BHK21 (Fig. 5C ), and Vero (Fig. 5D ) cells showed that r3LCMV/TransS was attenuated compared to r3LCMV/WT. Reduction in r3LCMV/TransS viral multiplication was further confirmed in each of these cell lines by flow cytometry analysis, and an approximately 1.5-to-4.5-fold decrease in GFP intensity compared with r3LCMV/WT-infected control cells was observed. These findings demonstrated the feasibility of implementing LCMV S segment reorganization for the generation of r3LCMV/TransS as live attenuated vaccine vectors.
Effect of NP expression levels on rLCMV/TransS fitness. To gain insights about the mechanism of impaired growth properties of rLCMV/TransS, we used reverse genetics techniques to rescue r3LCM viruses containing both the NP and GPC genes under the regulation of either the antigenome (r3LCMV/TransNP; Fig. 6A , bottom) or the genome (r3LCMV/TransGPC; Fig. 6B, bottom) promoters and compared their viral growth kinetics to that of r3LCMV/TransS. To prevent discrepancies in measurements of reporter gene expression under conditions of different UTRs, we used for comparison r3LCM viruses encoding GFP and Gluc in positions corresponding to those found in r3LCMV/TransNP (Fig. 6A, top) and r3LCMV/TransGPC (Fig. 6B, top) . Thus, r3LCMV/TransNP has GFP, but not Gluc, in the same locus (NP) as in the r3LCMV/TransS GFP/Gluc (Fig. 6A) . Likewise, r3LCMV/TransGPC has GFP in the same locus (GPC) as in the r3LCMV/TransS Gluc/GFP (Fig. 6B) but not Gluc. We observed that r3LCMV/TransNP replicated similarly to r3LCMV/TransS (Fig. 6C) . Quantification of GFP ϩ cells and analysis of the fluorescence intensity of r3LCMV/TransNP-infected cells showed GFP expression levels intermediate between those seen with r3LCMV/WT (higher) and r3LCMV/TransS (lower) (Fig. 6E) . Viral growth kinetics (Fig. 6G ) corroborated that r3LCMV/TransS and r3LCMV/TransNP exhibited similar degrees of attenuation in cultured cells. In contrast, r3LCMV/TransGPC-infected and r3LCMV/WT-infected cells expressed similar GFP levels ( Fig. 6D  and F) , and viral growth kinetics (Fig. 6H ) demonstrated that the two viruses also had similar replication capabilities. These results strongly suggest that reduced NP expression levels, rather than increased GPC expression levels, represent a main factor contributing to the impaired growth properties observed of rLCMV/ TransS.
Ability of rLCMV/TransS to persistent infect cells. As with most arenaviruses, LCMV has the ability to readily establish persistent infections in cultured cells. To examine whether rLCMV/ TransS retained this feature, we infected (MOI of 0.1) A549, BHK-21, and Vero cells with rLCMV/TransS, or with rLCMV/WT as a control, and after two passages, we examined the numbers of infected cells within the population by evaluating NP expression levels by immunofluorescence (Fig. 7) . Both rLCMV/WT and rLCMV/TransS were able to persist in all three cell lines tested.
DISCUSSION
There have been no vaccines against human diseases caused by arenavirus infections approved by the FDA to date, and current antiarenavirus therapy is limited to an off-label use of ribavirin that is only partially effective (17) (18) (19) (20) (21) . Rearrangement of viral genomes has recently been explored to generate attenuated viruses exhibiting properties amenable to the development of live attenuated vaccines, including DNA (37, 64) , double-stranded RNA (dsRNA) (38) , and positive-stranded (39) and negative-stranded (40-45, 65, 66) RNA viruses. However, similar viral genome reorganization has not yet been explored for the development of arenavirus vaccines. In this report, we examined as a proof of concept whether rearrangement of the S genome segment of LCMV resulted in an attenuated virus suitable for the development of a live attenuated arenavirus vaccine.
Using reporter gene-expressing MG assays, we found higher reporter expression levels from the NP locus than from the GPC locus (Fig. 1) . These results were further confirmed with the gen- a Six-week-old male B6 mice (n ϭ 8) were infected (i.c., 10 3 PFU) with rLCMV/WT or rLCMV/TransS viruses or were mock infected with PBS as a control. Mice were monitored daily for morbidity and mortality until the experimental endpoint (12 days p.i.).
eration of r3LCM viruses where reporter gene expression (both GFP and Gluc) was higher when expressed from the NP locus than when expressed from the GPC locus (Fig. 2) . We generated rLCMV/TransS, which contained a rearranged S segment (Fig. 3) and was attenuated both in cell culture (Fig. 4) and in vivo (Table  1) but was able, following a single immunization, to induce protective immunity to a lethal rLCMV/WT challenge ( Table 2) . Using a rescued r3LCMV/TransS virus (Fig. 5) , we obtained evidence that the impaired growth properties of the rearranged LCMV were associated with decreased NP expression levels rather than with increased GPC expression levels in infected cells (Fig. 6) .
Rearrangement of the arenavirus genome for the generation of live attenuated vaccine candidates offers several unique advantages over other current strategies. First, rearrangement of the viral genome makes viral reversion to a virulent form highly unlikely if not impossible. This strategy overcomes safety concerns affecting other live attenuated vaccine approaches currently licensed, which are based on a limited number of amino acid substitutions (67) . Particularly relevant to arenaviruses, a single amino acid mutation (F427I) within GP2 of the pathogenic XJ13 strain of JUNV attenuated XJ13 neurovirulence in suckling mice (25, 26) and was also highly attenuating in the guinea pig model of AHF although it was insufficient to prevent virus dissemination and mild clinical and pathological symptoms (68) . These findings suggest that similar limited genetic changes may result in reversion of Candid#1 to a more virulent form, which raises safety concerns and further supports arguments for the development of arenavirus live attenuated vaccines based on alternative approaches involving more drastic changes to the viral genome, such as the rearrangement of the viral genome proposed in the present study. Second, reassortment between a pathogenic arenavirus strain and a TransS-based live attenuated arenavirus vaccine is highly unlikely to generate a genetic combination of mutations or arrangement of genes associated with increased virulence compared to the already circulating pathogenic viral strain. Third, rearrangement of the arenavirus genome does not affect the viral protein sequence; thus, the live attenuated virus retains an intact antigenic repertoire identical to that of the WT virus. This intact repertoire should help to promote better B and T cell immune responses (32), representing an advantage over approaches using recombinant attenuated viral vectors expressing only one arenavirus antigen (27) (28) (29) (30) . Fourth, generation of live attenuated arenavirus vaccines based on rearrangement of the viral genome can be rapidly achieved using state-of-the-art plasmid-based reverse genetics technologies (58) (59) (60) 63) . Finally, the results of our studies indicate that attenuation of arenavirus by rearrangement of the viral genome is associated with reduced levels of NP expression during viral infection. This result opens the possibility of downregulating arenavirus NP expression levels as an approach for the development of novel arenavirus vaccines as well as antivirals aimed to decrease NP levels during viral infection. Altogether, our findings support the idea that rearrangement of the arenavirus genome might be effectively implemented for the development of safe and protective live attenuated vaccines to combat human-pathogenic arenaviruses. Moreover, this attenuation approach could be also used in combination with the triseg- mented arenavirus platform to facilitate the development of live attenuated vaccine vectors against different human pathogens.
